Skip to content

Hyris Fulfils Its Integration Into Ulisse Biomed to Give Birth to a New International Group Ready to Make Its Mark in the Global Biotech Market

Hyris 3 mins read

Following the first official announcement at the beginning of December last year, Hyris completed the transfer of its shares into Ulisse Biomed via a reverse take-over transaction. The new group, strong of flawless interoperability between its leading technologies, aims to become a new benchmark of innovation in the national and international biotech market.

LONDON, ENGLAND / ACCESSWIRE / January 15, 2024 / A new international biotech group was born from the integration of Hyris Ltd, an innovative biotech company renowned worldwide for its disruptive genetic testing platform, and Ulisse Biomed S.p.A., also known as UBM Group or "UBM" only, an Italian-based publicly traded biotech company appreciated for its innovative testing platforms.

Hyris Ulisse Corporate Integration
Hyris Ulisse Corporate Integration
A new benchmark in the biotech market

As anticipated on December 4th, the integration between Hyris and Ulisse Biomed was officially ratified on December 21st by completing a reverse take-over operation and following the shareholders' meeting of Ulisse Biomed held earlier on that same day, which also deliberated an increase of capital in option. The overarching goal is to give life to a new Italian segment of excellence in genetic analysis based on strong innovation competencies and ready to address international markets at scale.

The new Group, with strong roots in diagnostics, teranosis and healthcare, aims to create a strong actor operating as a leader in the in-vitro diagnostics industry, particularly molecular biology, thanks to flawless interoperability between its leading technologies.

Matteo Petti, CEO of Ulisse Biomed, who will keep his role of managing director in the new corporate structure, is very positive about the whole operation, highlighting how its implications go way beyond a mere financial transaction: "We are excited to announce the integration with Hyris. By joining forces, we will enhance our product offering, combining our experience and development capabilities with Hyris' unique mix of competencies. This integration aims to capitalise on the synergies between the two companies, maximising value for our shareholders and offering unprecedented integrated diagnostic solutions to our customers." He concludes: "The success of this operation projects us towards new horizons, and the joint management will work immediately to leverage the new strategic synergies."

The new structure aims to provide an integrated array of high-end performance products at a competitive cost to meet a diverse industry demand across various markets, defining a new portfolio of distinctive analytical capabilities at a global level.

Stefano Lo Priore, founder of Hyris and former CEO and recently appointed Chairman of UBM Group, agrees: "We are proud of this integration between Ulisse Biomed and Hyris. We have a joint industrial project with a strong vision and have already received excellent feedback from the market regarding the joint proposition of our solutions. As a united company, we will be able to implement the project in a synergic manner and create a unique and distinctive offer on the global and, even more so, on the Italian biotech scene." Priore is confident about the positive outcome of this operation: "Hyris and Ulisse Biomed are now officially part of the same team, united by common values and vision and a unique industrial. We are ready for the challenges that await us, strong of the competencies that the two companies will be able to pool together."

In the next months, the new management will put into action a strategic plan to accelerate team and resource integration, leveraging the two companies' similar cultures and shared values.

For more information, feel free to write an email to

Contact Information

Gabriele Salaris
Global Experience Manager
+39 345 555 3379



View the original press release on

More from this category

  • Biotechnology
  • 07/06/2024
  • 06:00
Centre for Eye Research Australia. Bionics Institute. Bionic Vision Technologies

Bionic eye trial reveals substantial vision improvements over two and a half years

Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years. Detailed outcomes from the trial, led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, are published in Ophthalmology Science. The findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye…

  • Biotechnology, Results Statistics
  • 31/05/2024
  • 07:54
The Lottery Corporation Ltd

Powerball Draw no. 1463

Official Results Powerball Draw no. 1463 Draw Date: Thursday, 30 May 2024 Drawn Numbers Winning Numbers 35 2 3 33 20 22 10 (drawn order) Powerball 9 Dividends Dividends Total Winners Total Prizes Payable Division 1 $0.00 0 $0.00 Division 2 $270,217.65 1 $270,217.65 Division 3 $9,598.45 35 $335,945.75 Division 4 $571.70 511 $292,138.70 Division 5 $192.00 1,141 $219,072.00 Division 6 $79.50 17,268 $1,372,806.00 Division 7 $49.50 21,547 $1,066,576.50 Division 8 $20.30 111,436 $2,262,150.80 Division 9 $11.90 326,742 $3,888,229.80 478,681 $9,707,137.20 Division 1 Jackpots to $12,000,000.00

  • Contains:
  • Biotechnology
  • 30/05/2024
  • 20:07
Moolec Science SA

Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update

LUXEMBOURG / ACCESSWIRE / May 30, 2024 / Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the third quarter of Fiscal Year 2024 ended March 31, 2024.Moolec Science Logo The main highlights of Moolec's business update are as follows:Piggy Sooy™ Product | Soybean Platform: Moolec's patented soybean product received USDA-APHIS Regulatory Status Review approval in April 2024.Safflower Platform: GLASO™ planting campaign progressing as expected. Two US Patents granted for production of chymosin in safflower seeds (SPC2) extended exclusive technology protection until 2041.Financial…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.